Teva Pharma (TEVA) Reports In-Line Q3 EPS, Offer FY Guidance

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $0.58, in-line with the analyst estimate of $0.58. Revenue for the quarter came in at $4 billion versus the consensus estimate of $4.07 billion.

GUIDANCE:

Teva Pharma sees FY2020 EPS of $2.40-$2.55, versus the consensus of $2.51. Teva Pharma sees FY2020 revenue of $16.5-16.8 billion, versus the consensus of $16.7 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
• Oilfield firm SLB's profit rises on international drilling demand
• Acme United (ACU) Misses Q1 EPS by 20c